CY1111215T1 - Αυξηση του επιπεδου αδενοσινης μεσω προκαλουμενης απο κυτοκινη εκφρασης toy cd73 - Google Patents

Αυξηση του επιπεδου αδενοσινης μεσω προκαλουμενης απο κυτοκινη εκφρασης toy cd73

Info

Publication number
CY1111215T1
CY1111215T1 CY20101100758T CY101100758T CY1111215T1 CY 1111215 T1 CY1111215 T1 CY 1111215T1 CY 20101100758 T CY20101100758 T CY 20101100758T CY 101100758 T CY101100758 T CY 101100758T CY 1111215 T1 CY1111215 T1 CY 1111215T1
Authority
CY
Cyprus
Prior art keywords
cytokine expression
adenosine level
increasing adenosine
expression toy
toy
Prior art date
Application number
CY20101100758T
Other languages
English (en)
Inventor
Sirpa Jalkanen
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20030467A external-priority patent/FI20030467A0/fi
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Publication of CY1111215T1 publication Critical patent/CY1111215T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Η παρούσα εφεύρεση αφορά μια μέθοδο που προκαλεί την αύξηση του επιπέδου αδενοσίνης σε κάποιο υποκείμενο μέσω χορήγησης στο εν λόγω υποκείμενο μιας αποτελεσματικής ποσότητας είτε i) ανασυνδυαστικής πρωτεΐνης CD73 είτε ii) μιας κυτοκίνης ή κάποιου άλλου παράγοντα ικανού να προκαλέσει έκφραση του ενδοθηλιακού CD73, ή έναν συνδυασμό αυτών. Επιπλέον, η εφεύρεση αφορά μια μέθοδο πρόληψης ή θεραπείας μιας νόσου ή μιας διαταραχής η οποία απαιτεί ή ωφελείται από την αύξηση του επιπέδου αδενοσίνης σε κάποιο υποκείμενο, όπως είναι οι φλεγμονώδεις καταστάσεις. Επίσης, η εφεύρεση αφορά μια μέθοδο αυξορρύθμισης της έκφρασης του ενδοθηλιακού CD73 σε κάποιο υποκείμενο μέσω της χορήγησης στο εν λόγω υποκείμενο μιας αποτελεσματικής ποσότητας κάποιας κυτοκίνης ή κάποιου άλλου παράγοντα ικανού να προκαλέσει έκφραση του ενδοθηλιακού CD73, και μια μέθοδο πρόληψης ή θεραπείας μιας νόσου ή μιας διαταραχής η οποία απαιτεί ή ωφελείται από την αυξορρύθμιση της έκφρασης του ενδοθηλιακού CD73.
CY20101100758T 2003-03-28 2010-08-17 Αυξηση του επιπεδου αδενοσινης μεσω προκαλουμενης απο κυτοκινη εκφρασης toy cd73 CY1111215T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20030467A FI20030467A0 (fi) 2003-03-28 2003-03-28 Menetelmä tulehdustilojen hoitamiseen
US51542503P 2003-10-30 2003-10-30
EP04721913A EP1608400B1 (en) 2003-03-28 2004-03-19 Elevation of adenosine level by cytokine-induced expression of cd73

Publications (1)

Publication Number Publication Date
CY1111215T1 true CY1111215T1 (el) 2015-06-11

Family

ID=33099764

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100758T CY1111215T1 (el) 2003-03-28 2010-08-17 Αυξηση του επιπεδου αδενοσινης μεσω προκαλουμενης απο κυτοκινη εκφρασης toy cd73

Country Status (9)

Country Link
US (3) US7534423B2 (el)
EP (1) EP1608400B1 (el)
JP (1) JP2011225607A (el)
AT (1) ATE471720T1 (el)
CA (1) CA2519465C (el)
CY (1) CY1111215T1 (el)
DE (1) DE602004027797D1 (el)
PL (1) PL1608400T3 (el)
WO (1) WO2004084933A1 (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070160645A1 (en) * 2001-10-25 2007-07-12 Jakob Vinten-Johansen PostConditioning System And Method For The Reduction Of Ischemic-Reperfusion Injury In The Heart And Other Organs
AU2002336650B2 (en) 2001-10-25 2008-06-05 Emory University Catheter for modified perfusion
DE602004027797D1 (de) * 2003-03-28 2010-08-05 Faron Pharmaceuticals Oy Erhöhung des adenosin-spiegels durch cytokin-induzierte expression von cd73
JP2008525468A (ja) * 2004-12-22 2008-07-17 エモリー・ユニバーシティ ポストコンディショニング臓器保護作用を増強する治療補助薬
FI20051003A0 (fi) * 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
US8975081B2 (en) 2007-10-24 2015-03-10 Faron Pharmaceuticals Oy Biomarker for monitoring development of diseases and assessing the efficacy of therapies
FI20070795A0 (fi) * 2007-10-24 2007-10-24 Faron Pharmaceuticals Oy Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
US20090130092A1 (en) * 2007-10-30 2009-05-21 Pinsky David J Nucleotide phosphate dissipation as a treatment for vascular disorders
WO2009106368A1 (en) * 2008-02-29 2009-09-03 Gelato Corporation N.V. Method for increasing the activity of the immune system of a mammal at risk of inflammatory diseases
US20110064671A1 (en) * 2008-03-10 2011-03-17 Cornell University Modulation of blood brain barrier permeability
CN102666581A (zh) 2009-08-31 2012-09-12 艾普利穆恩公司 用于抑制移植物排斥的方法和组合物
EP2588123A2 (en) 2010-06-30 2013-05-08 Compugen Ltd. C1orf32 for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
CU23963B1 (es) * 2011-07-01 2013-12-11 Ct De Ingeniería Genética Y Biotecnología Composiciones farmacéuticas a partir de derivados de la c-ficocianina y combinaciones con interferones del tipo i para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas
US20140234373A1 (en) 2011-09-16 2014-08-21 Georfia Regents University Methods of Promoting Immune Tolerance
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
WO2014100483A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. Anti-human b7-h4 antibodies and their uses
CN108351687B (zh) 2015-09-04 2022-01-07 耶鲁大学 靶向胰腺和结肠的聚合胆汁酸纳米组合物
FI126979B (en) 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and use thereof
WO2017155981A1 (en) 2016-03-07 2017-09-14 Massachusetts Institute Of Technology Protein-chaperoned t-cell vaccines
WO2017173453A1 (en) 2016-04-01 2017-10-05 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
BR112019005292A2 (pt) 2016-09-21 2019-09-03 Nextcure Inc anticorpos para siglec-15 e métodos de uso dos mesmos.
EP4360714A2 (en) 2016-09-21 2024-05-01 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
IL272909B2 (en) 2017-09-07 2024-01-01 Univ Res Inst Inc Augusta A specific AKT3 activator and its uses
CA3123886A1 (en) 2019-01-17 2020-07-23 James DAHLMAN Drug delivery systems containing oxidized cholesterols

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3650715T2 (de) 1985-10-14 1999-06-24 Yeda Res & Dev Verwendung von menschlichem Interferon-Beta 2A für die Herstellung von Medikamenten
GB9702021D0 (en) * 1997-01-31 1997-03-19 Imperial College Medicaments
KR20020053064A (ko) * 1999-09-28 2002-07-04 아마릴로 바이오싸이언시스, 인크 질병 치료를 위한 저용량의 ｉｆｎ-감마
ATE367168T1 (de) * 2001-04-03 2007-08-15 Cytech B V U Behandlung von hypoxya/ischaemia blutflusswiderstand mit beta-interferon
AU2002310922A1 (en) 2001-05-04 2002-11-18 Institute Of Molecular And Cell Biology Interferons in the treatment of ischemia
US6911198B2 (en) 2001-09-17 2005-06-28 Yeda Research And Development Co. Ltd. Method and pharmaceutical composition for treating inflammation
CA2477577A1 (en) 2002-03-12 2003-09-18 Maxygen Aps Interferon beta-like molecules for treatment of stroke
DE602004027797D1 (de) 2003-03-28 2010-08-05 Faron Pharmaceuticals Oy Erhöhung des adenosin-spiegels durch cytokin-induzierte expression von cd73

Also Published As

Publication number Publication date
JP2011225607A (ja) 2011-11-10
CA2519465A1 (en) 2004-10-07
US20060198821A1 (en) 2006-09-07
PL1608400T3 (pl) 2010-11-30
DE602004027797D1 (de) 2010-08-05
EP1608400B1 (en) 2010-06-23
US20090269303A1 (en) 2009-10-29
WO2004084933A1 (en) 2004-10-07
US7727521B2 (en) 2010-06-01
EP1608400A1 (en) 2005-12-28
ATE471720T1 (de) 2010-07-15
CA2519465C (en) 2016-08-02
US20060034801A1 (en) 2006-02-16
US7534423B2 (en) 2009-05-19

Similar Documents

Publication Publication Date Title
CY1111215T1 (el) Αυξηση του επιπεδου αδενοσινης μεσω προκαλουμενης απο κυτοκινη εκφρασης toy cd73
EA201071128A1 (ru) Карбануклеозидные аналоги для противовирусной терапии
CY1118836T1 (el) Αντι-ιϊκα φωσφονικα αναλογα
TW200716612A (en) Pyrimidine compounds
EA200700363A1 (ru) Фосфонатные аналоги соединений ингибиторов вич
WO2007142755A3 (en) Purine analogs
CL2004002050A1 (es) Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
EG26731A (en) Equivalent human antibodies as IFN-ادات antagonists and act as selective inhibitors of IFN- ر
BRPI0414867A (pt) pirazolopiridinas e seus análogos
ECSP099079A (es) Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos
TNSN06228A1 (en) Compounds and methods of use
TW200614996A (en) Antiviral compounds
BRPI0409680A (pt) análogos de fosfonato anti-cáncer
HN2004000146A (es) Dihidroquinazolinas sustituidas
TW200633995A (en) Andrographolide derivatives to treat viral infections
EA200970375A1 (ru) Соединения и способы лечения вируса гепатита с
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
CL2004000710A1 (es) Composicion antimicrobiana y antiparasitaria formada por un antibiotico derivado del cloranfenicol o tianfenicol, un endectocida y por lo menos un vehiculo aceptable, y su uso para tratar enfermedades respiratorias y parasitarias de los bovinos.
WO2005092878A3 (en) Schweinfurthin analogues
HK1112228A1 (en) Substituted azachinzolines having an antiviral action
DK1824504T3 (da) Anti-tumor-kombinationer, der indeholder VEGF-trap og 5-fluoruracil eller et derivat deraf
DE602005010844D1 (de) Pharmazeutische zusammensetzungen mit interferon-tau
WO2009108252A3 (en) Method for stimulating immune response against moraxella catarrhalis
DE602004009166D1 (de) Neue Analoga von Nitrobenzylthioinosin
ATE398134T1 (de) Neue analoga von nitrobenzylthioinosin